Literature DB >> 26416856

Genome Expression Profiling-Based Identification and Administration Efficacy of Host-Directed Antimicrobial Drugs against Respiratory Infection by Nontypeable Haemophilus influenzae.

Begoña Euba1, Javier Moleres2, Víctor Segura3, Cristina Viadas2, Pau Morey4, David Moranta5, José Leiva6, Juan Pablo de-Torres7, José Antonio Bengoechea8, Junkal Garmendia9.   

Abstract

Therapies that are safe, effective, and not vulnerable to developing resistance are highly desirable to counteract bacterial infections. Host-directed therapeutics is an antimicrobial approach alternative to conventional antibiotics based on perturbing host pathways subverted by pathogens during their life cycle by using host-directed drugs. In this study, we identified and evaluated the efficacy of a panel of host-directed drugs against respiratory infection by nontypeable Haemophilus influenzae (NTHi). NTHi is an opportunistic pathogen that is an important cause of exacerbation of chronic obstructive pulmonary disease (COPD). We screened for host genes differentially expressed upon infection by the clinical isolate NTHi375 by analyzing cell whole-genome expression profiling and identified a repertoire of host target candidates that were pharmacologically modulated. Based on the proposed relationship between NTHi intracellular location and persistence, we hypothesized that drugs perturbing host pathways used by NTHi to enter epithelial cells could have antimicrobial potential against NTHi infection. Interfering drugs were tested for their effects on bacterial and cellular viability, on NTHi-epithelial cell interplay, and on mouse pulmonary infection. Glucocorticoids and statins lacked in vitro and/or in vivo efficacy. Conversely, the sirtuin-1 activator resveratrol showed a bactericidal effect against NTHi, and the PDE4 inhibitor rolipram showed therapeutic efficacy by lowering NTHi375 counts intracellularly and in the lungs of infected mice. PDE4 inhibition is currently prescribed in COPD, and resveratrol is an attractive geroprotector for COPD treatment. Together, these results expand our knowledge of NTHi-triggered host subversion and frame the antimicrobial potential of rolipram and resveratrol against NTHi respiratory infection.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26416856      PMCID: PMC4649218          DOI: 10.1128/AAC.01278-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  66 in total

1.  Cross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi.

Authors:  Seiko Susuki-Miyata; Masanori Miyata; Byung-Cheol Lee; Haidong Xu; Hirofumi Kai; Chen Yan; Jian-Dong Li
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-23       Impact factor: 11.205

Review 2.  Resveratrol: a multifunctional cytoprotective molecule.

Authors:  Bela Juhasz; Balazs Varga; Rudolf Gesztelyi; Adam Kemeny-Beke; Judit Zsuga; Arpad Tosaki
Journal:  Curr Pharm Biotechnol       Date:  2010-12       Impact factor: 2.837

Review 3.  Genotypic and phenotypic diversity of the noncapsulated Haemophilus influenzae: adaptation and pathogenesis in the human airways.

Authors:  Junkal Garmendia; Pau Martí-Lliteras; Javier Moleres; Carmen Puig; José A Bengoechea
Journal:  Int Microbiol       Date:  2012-12       Impact factor: 2.479

Review 4.  Statins as adjunct therapy in COPD: how do we cope after STATCOPE?

Authors:  Robert P Young; Raewyn J Hopkins; Alvar Agusti
Journal:  Thorax       Date:  2014-07-11       Impact factor: 9.139

5.  Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease.

Authors:  Timothy F Murphy; Aimee L Brauer; Andrew T Schiffmacher; Sanjay Sethi
Journal:  Am J Respir Crit Care Med       Date:  2004-04-29       Impact factor: 21.405

6.  A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9.

Authors:  Yuji Nakamaru; Chaitanya Vuppusetty; Hiroo Wada; Jill C Milne; Misako Ito; Christos Rossios; Mark Elliot; James Hogg; Sergei Kharitonov; Hajime Goto; Jean E Bemis; Peter Elliott; Peter J Barnes; Kazuhiro Ito
Journal:  FASEB J       Date:  2009-04-17       Impact factor: 5.191

Review 7.  Roflumilast in the management of chronic obstructive pulmonary disease.

Authors:  Melissa Lipari; Harpreet Benipal; Pramodini Kale-Pradhan
Journal:  Am J Health Syst Pharm       Date:  2013-12-01       Impact factor: 2.637

8.  Statins decrease lung inflammation in mice by upregulating tetraspanin CD9 in macrophages.

Authors:  Yingji Jin; Isao Tachibana; Yoshito Takeda; Ping He; Sujin Kang; Mayumi Suzuki; Hanako Kuhara; Satoshi Tetsumoto; Kazuyuki Tsujino; Toshiyuki Minami; Takeo Iwasaki; Kaori Nakanishi; Satoshi Kohmo; Haruhiko Hirata; Ryo Takahashi; Koji Inoue; Izumi Nagatomo; Hiroshi Kida; Takashi Kijima; Mari Ito; Hideyuki Saya; Atsushi Kumanogoh
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

9.  Characterization of nontypable Haemophilus influenzae isolates recovered from adult patients with underlying chronic lung disease reveals genotypic and phenotypic traits associated with persistent infection.

Authors:  Junkal Garmendia; Cristina Viadas; Laura Calatayud; Joshua Chang Mell; Pau Martí-Lliteras; Begoña Euba; Enrique Llobet; Carmen Gil; José Antonio Bengoechea; Rosemary J Redfield; Josefina Liñares
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

10.  Host-directed antimicrobial drugs with broad-spectrum efficacy against intracellular bacterial pathogens.

Authors:  Daniel M Czyż; Lakshmi-Prasad Potluri; Neeta Jain-Gupta; Sean P Riley; Juan J Martinez; Theodore L Steck; Sean Crosson; Howard A Shuman; Joëlle E Gabay
Journal:  MBio       Date:  2014-07-29       Impact factor: 7.867

View more
  8 in total

1.  New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria.

Authors:  Jourdan A Andersson; Eric C Fitts; Michelle L Kirtley; Duraisamy Ponnusamy; Alex G Peniche; Sara M Dann; Vladimir L Motin; Sadhana Chauhan; Jason A Rosenzweig; Jian Sha; Ashok K Chopra
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

2.  Combating Multidrug-Resistant Pathogens with Host-Directed Nonantibiotic Therapeutics.

Authors:  Jourdan A Andersson; Jian Sha; Michelle L Kirtley; Emily Reyes; Eric C Fitts; Sara M Dann; Ashok K Chopra
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

3.  Resveratrol therapeutics combines both antimicrobial and immunomodulatory properties against respiratory infection by nontypeable Haemophilus influenzae.

Authors:  Begoña Euba; Nahikari López-López; Irene Rodríguez-Arce; Ariadna Fernández-Calvet; Montserrat Barberán; Nuria Caturla; Sara Martí; Roberto Díez-Martínez; Junkal Garmendia
Journal:  Sci Rep       Date:  2017-10-16       Impact factor: 4.379

4.  Quercetin inhibits NTHi-triggered CXCR4 activation through suppressing IKKα/NF-κB and MAPK signaling pathways in otitis media.

Authors:  Yu-Kun Ma; Yu-Bin Chen; Peng Li
Journal:  Int J Mol Med       Date:  2018-03-20       Impact factor: 4.101

5.  Transformed Recombinant Enrichment Profiling Rapidly Identifies HMW1 as an Intracellular Invasion Locus in Haemophilus influenza.

Authors:  Joshua Chang Mell; Cristina Viadas; Javier Moleres; Sunita Sinha; Ariadna Fernández-Calvet; Eric A Porsch; Joseph W St Geme; Corey Nislow; Rosemary J Redfield; Junkal Garmendia
Journal:  PLoS Pathog       Date:  2016-04-28       Impact factor: 6.823

6.  Inactivation of the Thymidylate Synthase thyA in Non-typeable Haemophilus influenzae Modulates Antibiotic Resistance and Has a Strong Impact on Its Interplay with the Host Airways.

Authors:  Irene Rodríguez-Arce; Sara Martí; Begoña Euba; Ariadna Fernández-Calvet; Javier Moleres; Nahikari López-López; Montserrat Barberán; José Ramos-Vivas; Fe Tubau; Carmen Losa; Carmen Ardanuy; José Leiva; José E Yuste; Junkal Garmendia
Journal:  Front Cell Infect Microbiol       Date:  2017-06-20       Impact factor: 5.293

7.  Modulation of Haemophilus influenzae interaction with hydrophobic molecules by the VacJ/MlaA lipoprotein impacts strongly on its interplay with the airways.

Authors:  Ariadna Fernández-Calvet; Irene Rodríguez-Arce; Goizeder Almagro; Javier Moleres; Begoña Euba; Lucía Caballero; Sara Martí; José Ramos-Vivas; Toby Leigh Bartholomew; Xabier Morales; Carlos Ortíz-de-Solórzano; José Enrique Yuste; José Antonio Bengoechea; Raquel Conde-Álvarez; Junkal Garmendia
Journal:  Sci Rep       Date:  2018-05-02       Impact factor: 4.379

8.  Preclinical Evaluation of the Antimicrobial-Immunomodulatory Dual Action of Xenohormetic Molecules against Haemophilus influenzae Respiratory Infection.

Authors:  Ariadna Fernández-Calvet; Begoña Euba; Lucía Caballero; Roberto Díez-Martínez; Margarita Menéndez; Carlos Ortiz de Solórzano; José Leiva; Vicente Micol; Enrique Barrajón-Catalán; Junkal Garmendia
Journal:  Biomolecules       Date:  2019-12-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.